Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S (NOVO B)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Business Summary
Logo Novo Nordisk A/S
Develops, manufactures, markets and distributes pharmaceutical products

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products.

It operates through the following business segments: Diabetes & Obesity Care, and Biopharmaceuticals.

The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity.

The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy.

The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Number of employees : 42 076 persons.
Sales per Businesses
20162017Delta
DKK (in Million)%DKK (in Million)%
Diabetes Care and Obesity88,94979.6%92,87783.2% +4.42%
Biopharmaceuticals22,83120.4%18,81916.8% -17.57%
Sales per Regions
20162017Delta
DKK (in Million)%DKK (in Million)%
United States57,19451.2%55,83150% -2.38%
Europe20,68218.5%21,18919% +2.45%
International14,05012.6%---
China10,4589.4%10,7099.6% +2.4%
Pacific9,3968.4%---
Africa, Asia, Middle East & Oceania--12,01810.8%-
Japan & Korea--6,0725.4%-
Latin America--3,6993.3%-
Canada--2,1781.9%-
Managers
NameAgeSinceTitle
Lars Fruergaard Jørgensen, MBA521991President & Chief Executive Officer
Helge Lund, MBA552017Chairman
Maziar Mike Doustdar481992Executive Vice President-International Operations
Karsten Munk Knudsen46-Chief Financial Officer
Mads Krogsgaard Thomsen, PhD581991Chief Science Officer & Executive Vice President
Alan C. Moses, MD-2008Senior Vice President & Chief Medical Officer
Anne Marie Handrup Kverneland621981Director
Stig Strøbæk541992Director
Elizabeth Anne Hewitt622012Independent Director
Søren Thuesen Pedersen, MBA541994Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 1,912,564,000 1,734,159,904 90.7% 56,000,000 2.9% 70.8%
Share B 10 537,436,000 0 0.0% 0 0.0%
Shareholders
NameEquities%
Novo Nordisk Fonden 157,310,695 8.23%
The Vanguard Group, Inc. 44,330,099 2.32%
Norges Bank Investment Management 43,113,675 2.25%
Alecta Pension Insurance Mutual 28,698,000 1.50%
Novo Nordisk A/S 27,768,941 1.45%
BlackRock Fund Advisors 22,296,197 1.17%
Jupiter Asset Management Ltd. 18,793,348 0.98%
Capital Research & Management Co. (World Investors) 17,828,910 0.93%
Flossbach von Storch AG 17,807,590 0.93%
BlackRock Investment Management (UK) Ltd. 14,550,530 0.76%
Holdings
NameEquities%Valuation
Novo Nordisk A/S (NOVO B) 27,768,9411.45%1,317,125,580 USD
Nnit A/S (NNIT) 4,375,00017.5%110,463,325 USD
Innate Pharma (IPH) 8,908,45615.5%57,037,637 USD
Affimed NV (AFMD) 2,663,8304.27%5,727,235 USD
Pieris Pharmaceuticals Inc (PIRS) 0
Company contact information
Novo Nordisk A/S
Novo Allé
Bagsværd, Capital Region 2880

Phone : +45.44.44.88.88
Web : www.novonordisk.com
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
NOVO NORDISK A/S-13.74%85 393
JOHNSON & JOHNSON-12.27%328 751
PFIZER0.00%211 871
NOVARTIS-10.17%188 057
ROCHE HOLDING LTD.-12.19%183 625
MERCK AND COMPANY8.90%164 189
AMGEN7.07%123 203
ABBOTT LABORATORIES9.23%109 294
BAYER-5.32%104 138
GLAXOSMITHKLINE17.20%101 051
SANOFI-4.93%97 676
ELI LILLY AND COMPANY2.79%94 237
ASTRAZENECA5.04%89 519
BRISTOL-MYERS SQUIBB COMPANY-12.47%87 677
ALLERGAN PLC5.79%58 675
CELGENE CORPORATION-23.88%57 580
SHIRE2.82%47 913
JIANGSU HENGRUI MEDICINE CO LTD48.77%44 755
ASTELLAS PHARMA INC21.52%31 515
TAKEDA PHARMACEUTICAL CO LTD-33.82%30 885
CHUGAI PHARMACEUTICAL CO LTD3.99%30 337
Connections : Novo Nordisk A/S
NNE Pharmaplan A/S
Hofor Forsyning Komplementar A/S
P/f Tjaldur
International Crisis Group
Tjaldur P/F
Harno Invest A/S
Schlumberger AG
Melrose Holdings Ltd.
Steno Diabetes Center A/S
Silverwood Property Ltd.
University of Copenhagen
HOFOR Forsyning Holding P/S
Novo Nordisk Fonden
Hofor Forsyning A/S
© 2018 People , Fundamentals and Ownership